E ESPERION THERAPEUTICS INC NE
| Market Cap | $670.28M |
| P/E Ratio | — |
| Forward P/E | 8.90 |
| Dividend Yield | — |
| Beta | 1.17 |
| 52W Range | $0.73 - $4.08 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 0.00% | $430.00K | 116,292 | Buy |
Insider Trading
| Insider Name of the company insider who made the trade 9 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Halladay BenjaminChief Financial Officer | Sale | 6,424 | $2.71 | $17.38K | 17 Mar 2026 | 17 Mar 2026 |
| Koenig Sheldon L.President and CEO | Sale | 25,578 | $2.72 | $69.55K | 17 Mar 2026 | 17 Mar 2026 |
| Looker BenjaminChief Legal Officer | Sale | 5,708 | $2.70 | $15.43K | 17 Mar 2026 | 17 Mar 2026 |
| Looker BenjaminGeneral Counsel | Sale | 1,689 | $2.88 | $4.87K | 20 Jan 2026 | 21 Jan 2026 |
| Looker BenjaminGeneral Counsel | Sale | 6,517 | $3.67 | $23.90K | 17 Dec 2025 | 18 Dec 2025 |
| Halladay BenjaminChief Financial Officer | Sale | 7,337 | $3.67 | $26.90K | 17 Dec 2025 | 18 Dec 2025 |
| Koenig Sheldon L.President and CEO | Sale | 48,244 | $3.67 | $177.20K | 17 Dec 2025 | 18 Dec 2025 |
| Looker BenjaminGeneral Counsel | Sale | 1,248 | $2.62 | $3.28K | 17 Oct 2025 | 20 Oct 2025 |
| Benjamin LookerGeneral Counsel | Sale | 1,248 | $2.62 | $3.28K | 17 Oct 2025 | 20 Oct 2025 |
Frequently Asked Questions
What is ESPR stock price today?
ESPERION THERAPEUTICS INC NE (ESPR) is currently trading at $2.61. The stock has a 52-week range of $0.73 to $4.08 and a market capitalization of $670.28M.
Is ESPR a good stock to buy in 2026?
ESPERION THERAPEUTICS INC NE has a P/E ratio of N/A (forward P/E: 8.9), a dividend yield of none, and 1-year performance of +102.3%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling ESPR stock?
There have been 9 insider transactions for ESPR in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has ESPR stock performed over the past year?
ESPERION THERAPEUTICS INC NE (ESPR) has returned +102.3% over the past 12 months. The stock traded between $0.73 and $4.08 during this period, and is currently at $2.61.
Which hedge funds own ESPR (ESPERION THERAPEUTICS INC NE)?
1 tracked hedge funds currently hold ESPR in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is ESPR's market cap and valuation?
ESPERION THERAPEUTICS INC NE (ESPR) has a market capitalization of $670.28M. The trailing P/E ratio is N/A and forward P/E is 8.9. The stock is classified in the Healthcare sector.
What is ESPR's revenue and profitability?
ESPERION THERAPEUTICS INC NE reported revenue of $403.14M with net income of N/A and a profit margin of N/A. The stock has a beta of 1.17.
What sector is ESPR in and who are its biggest institutional holders?
ESPERION THERAPEUTICS INC NE (ESPR) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.